Aarti Industries Ltd Q2 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/4ux3azdt6ojhtby51mq12z1y.pdf

Key Takeaways


Demand Environment

Rajendra Gogri: "We expect the worst to be over in H1 FY24 and anticipate that it will take a few more quarters for normalised demand across various end segments/product lines. Thus we expect consequentially better performance in H2FY24 and foresee FY25 to be a normalising year considering the current pace of recovery."

Margin Trajectory & Mix Shift


Long-Term Contracts: Status & Visibility


Capex, Debt & Project Pipeline

Chetan Gandhi: "I believe it should peak-out somewhere in FY26, and from there it will start tapering off. Putting a number at this point of time would be a bit difficult."

Product & End-Market Dynamics

SegmentTrendCommentary
Polymers & Additives▲ GrowthSaw volume growth in the quarter.
Dyestuff▲ ImprovingSome recovery visible along with a few specialty applications.
Agrochemicals▼ ChallengingMolecule-specific demand; the major contributor to the 17% sequential domestic sales decline.
Home & Personal Care▬ Limited exposureSome demand pressure but not a material output for the company.
Nitro Toluene▼ Volume declineFell QoQ due to agrochemical demand and some planned shutdowns. No known restriction on Metalochlorine sales in Europe.
Octane Booster▲ Stable+Expected to sustain and possibly grow demand.

Guidance & Commitments

CommitmentSpecificsTimeline
FY24 EBITDA₹950–1,000 crore, with H2 upward of ₹500 croreFY24 full year
FY25 EBITDA vs earlier ₹1,700 crore guidanceAt least 5% to 15% decline from ₹1,700 crore, with QoQ increases as demand recovers and new plants commissionFY25
Demand normalizationDemand expected to get normalized; FY25 a normalizing yearH1 calendar year 2024 / FY25
Ethylation & NT expansion commissioningTargeting end of Q1 FY25; progressive volume and EBITDA increase through FY25, H2 better than H1End-Q1 FY25 onward
Contract-III contributionNo significant EBITDA in FY24; major gain in FY25FY25
Contract-I plant decisionEvaluation continues; decision in a couple more quarters~Q4 FY24 / Q1 FY25
Net debt peakExpected to peak out in FY26, then taper offFY26
Two-year capex plan₹2,500–3,000 crore; no change plannedThrough FY25

Key Metrics

MetricQ2 FY24
Revenue₹1,597 cr, up 2% QoQ
EBITDA₹233 cr, up 16% QoQ
Profit after tax₹91 cr, up 30% QoQ
H1 FY24 EBITDA₹433 cr
H2 FY24 EBITDA visibilityupward of ₹500 cr
FY24 EBITDA guidance₹950–1,000 cr
FY25 EBITDA guidance₹1,450–1,600 cr, 5–15% decline from earlier ₹1,700 cr guidance
Nitrochlorobenzene production19,014 MT, vs 20,276 MT in Q2 FY23 and 17,293 MT in Q1 FY24
Hydrogenation production3,136 TPM, vs 2,558 TPM in Q2 FY23 and 2,868 TPM in Q1 FY24
Nitrotoluene production7,560 MT, vs 4,954 MT in Q2 FY23 and 9,320 MT in Q1 FY24
PDA volumes316 tons per month
H1 FY24 CAPEX₹575 cr
FY24 target CAPEX₹1,200–1,300 cr
Two-year CAPEX commitment₹2,500–3,000 cr
Net debt₹2,700–2,800 cr, cash of ₹400+ cr, gross debt ~₹3,200 cr
Net debt by end FY24 (worst-case)₹2,900 cr
Non-regular export markets share~10% of total exports
Export mix range40% to 55%
Asset turn for new assets1.2x to 1.3x
Interest cost revaluation loss₹12 cr, on unhedged long-term loans